Pinteon Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.pinteon.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)
Phase 1
Terminated
- Conditions
- Traumatic Brain Injury
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Pinteon Therapeutics, Inc
- Target Recruit Count
- 1
- Registration Number
- NCT04677829
- Locations
- 🇺🇸
Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
Safety and Tolerability of PNT001 in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboBiological: PNT001
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Pinteon Therapeutics, Inc
- Target Recruit Count
- 49
- Registration Number
- NCT04096287
- Locations
- 🇺🇸
Woodland Research Northwest, Rogers, Arkansas, United States
🇺🇸Pacific Research Network, Inc., San Diego, California, United States
🇺🇸Hassman Research Institute, Marlton, New Jersey, United States
News
No news found